In part 6 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about cardiovascular disease and type 2, and the impact of heart disease on the patient with diabetes.
Thomas Seck, MD, is VP of Clinical Development and Medical Affairs at Boehringer Ingelheim.
Transcript of this video segment:
Steve: But for type 2 diabetes, what’s the impact on cardiovascular disease that we are talking about in type 2 diabetes?
Dr. Seck: It has huge implications for patients. I started in very beginning sharing with you the impact on life expectancy. The reduction of 12 years of your life taken away if you are diagnosed with type 2 diabetes and cardiovascular disease at an age 60. I think that’s very tangible for patients. On top of that, we talked about impact on costs. Managing cardiovascular disease is very expensive. That’s another financial piece to it.